AU Patent

AU2022245300B2 — Device for treating anaphylaxis

Assigned to Kokua Pharma Inc · Expires 2026-04-02 · 0y expired

What this patent protects

The present disclosure provides a metered dose inhaler (MDI) comprising an API formulation suitable for administration to a patient in need thereof by inhalation, as well as methods and uses of the MDI.

USPTO Abstract

The present disclosure provides a metered dose inhaler (MDI) comprising an API formulation suitable for administration to a patient in need thereof by inhalation, as well as methods and uses of the MDI.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022245300B2
Jurisdiction
AU
Classification
—
Expires
2026-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Kokua Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.